Is AOD-9604 Legal in Maryland?

What AOD-9604 Actually Is

AOD-9604 is a synthetic fragment of human growth hormone (hGH), specifically the C-terminal peptide spanning amino acid residues 177 to 191. The sequence was isolated because that region of hGH appears to carry the lipolytic (fat-breakdown) signaling activity without the insulin-like or anabolic effects associated with full-length hGH [1]. Researchers at Monash University in Australia spent much of the late 1990s and early 2000s characterizing this fragment in animal models, then moved into human trials under the commercial name Tyr-hGH Frag 176-191.

How It Differs From Full HGH

Full-length recombinant hGH (somatropin) is an FDA-approved drug with multiple brand names (Norditropin, Genotropin, Humatrope) and tightly controlled prescribing indications [2]. AOD-9604 is not somatropin. It does not bind the GH receptor in the same way, and it does not raise IGF-1 concentrations meaningfully at doses used in human studies. That distinction matters for regulatory classification.

The METASIN Trials

Metabolic Pharmaceuticals Ltd. Ran a series of phase II trials, collectively referred to as the METASIN program, evaluating oral AOD-9604 (brand name Tyr-hGH Frag) in overweight adults. The largest, METASIN-1, enrolled 300 participants and tested doses from 1 mg to 30 mg per day over 12 weeks. At 1 mg per day, subjects lost a statistically significant 2.8 kg more than placebo. Higher doses did not produce proportionally greater losses. The company ultimately did not file a New Drug Application (NDA) with the FDA, so AOD-9604 never crossed into approved-drug territory [3].

Federal Legal Framework: Where AOD-9604 Stands Today

The federal picture is the foundation of any state-level analysis. Maryland cannot unilaterally legalize something that federal law prohibits, and it cannot restrict something purely because the FDA has declined to approve it.

FDA Approval Status

AOD-9604 has no FDA approval for any indication in any route of administration. Unapproved drugs may not be marketed in interstate commerce under the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. §321 et seq. [4]. However, "not approved" is not the same as "illegal to prescribe." Physicians routinely prescribe approved drugs off-label, and compounding pharmacies have a separate statutory pathway.

The 503A Compounding Pharmacy Pathway

Section 503A of the FD&C Act permits state-licensed compounding pharmacies to prepare individualized preparations for specific patients when a licensed prescriber writes a prescription. The catch: the active pharmaceutical ingredient (API) must either be in an FDA-approved finished drug product or appear on the FDA's 503A Bulks List, which authorizes specific bulk substances for compounding [5].

AOD-9604 was reviewed by the FDA's Pharmacy Compounding Advisory Committee. In 2022 and 2023, the agency published its evaluation, finding that AOD-9604 lacked sufficient clinical evidence of safety and effectiveness for the compounded route (injectable). As a result, it was placed on the list of bulk substances that may NOT be compounded under 503A [6]. That decision applies nationally, including Maryland.

The 503B Outsourcing Facility Pathway

Section 503B outsourcing facilities can compound larger batches for hospitals and physician offices, but they face even stricter requirements. They may only use bulk substances that the FDA has specifically authorized. AOD-9604 has not received that authorization [5]. A 503B facility compounding AOD-9604 for office stock would be operating outside federal law.

The GRAS Designation Confusion

Metabolic Pharmaceuticals did obtain a Generally Recognized As Safe (GRAS) self-affirmation for oral AOD-9604 in a food context, sometimes cited in marketing materials as evidence of federal approval. The FDA's GRAS process applies to food additives, not drug products [7]. GRAS status does not permit any pharmacy to compound an injectable formulation of AOD-9604, and it does not constitute FDA drug approval.

Is AOD-9604 a Controlled Substance?

No. The Drug Enforcement Administration has not scheduled AOD-9604 under the Controlled Substances Act. It does not appear in DEA Schedule I, II, III, IV, or V [8]. Maryland's Controlled Dangerous Substances Act mirrors federal scheduling; because AOD-9604 is not federally scheduled, Maryland has no separate scheduling either. Possession without dispensing intent is not a criminal offense under either federal or Maryland controlled-substance statutes.

Maryland-Specific Legal Analysis

Maryland does not have a state statute that specifically addresses AOD-9604. The state's approach to pharmaceutical compounding and prescribing flows through three main bodies of law.

Maryland Board of Pharmacy

The Maryland Board of Pharmacy licenses and regulates pharmacies operating in the state under the Maryland Pharmacy Act, Md. Code, Health Occ. §12-101 et seq. Maryland's 503A-equivalent pharmacies must comply with USP <795> and USP <797> standards and with federal bulk-substance restrictions [9]. Because the FDA has placed AOD-9604 on the prohibited bulk-substance list for 503A compounding, a Maryland-licensed compounding pharmacy cannot legally prepare injectable AOD-9604 for a patient-specific prescription under current federal guidance.

Maryland Medical Practice Act

Maryland physicians practice under Md. Code, Health Occ. §14-101 et seq. The Medical Practice Act does not enumerate which drugs or peptides a physician may or may not prescribe; that authority flows from federal drug-approval status and DEA scheduling. A Maryland physician who prescribes AOD-9604 from a pharmacy that cannot legally compound it may be directing a patient to an unlawful product source, which could constitute unprofessional conduct under the Board's standards [10].

Telehealth and Out-of-State Compounders

Some telehealth clinics market AOD-9604 and instruct patients to obtain it from online pharmacies registered in other states or from international sources. Maryland's telehealth statute (Md. Code, Health-Gen. §19-141) requires that a prescriber hold a Maryland license or qualify under an interstate compact when treating Maryland residents. Obtaining AOD-9604 from an unregistered foreign compounder violates both the FD&C Act's drug importation provisions and Maryland's prohibition on unlicensed pharmacy practice. That pathway is not legally sound.

The Current Gray Area: Practical Reality for Maryland Patients

The following four-quadrant framework helps Maryland patients and clinicians assess where any specific AOD-9604 offer actually falls on the legality spectrum.

Quadrant 1 (Compliant). A Maryland-licensed physician with a documented patient relationship prescribes a compounded product from a pharmacy that is NOT using AOD-9604 as the active ingredient but rather a related compound that remains on the 503A permissible list. Some clinicians pivot to alternative lipolytic peptides (e.g., tesamorelin, which is FDA-approved for HIV-associated lipodystrophy) when the patient's clinical picture fits [11].

Quadrant 2 (Uncertain). A Maryland physician prescribes AOD-9604 from a 503A pharmacy that argues it complies with pre-2023 guidance or relies on a grandfathering interpretation. FDA enforcement discretion has historically been inconsistent, so some pharmacies continue operating under this rationale. The legal risk sits with the pharmacy and, to a lesser extent, the prescriber.

Quadrant 3 (Non-Compliant). A telehealth clinic ships injectable AOD-9604 prepared by an unregistered compounder directly to a Maryland address. This violates the FD&C Act's prohibitions on interstate commerce of unapproved drugs and Maryland pharmacy law.

Quadrant 4 (Non-Compliant). A patient purchases AOD-9604 labeled "for research use only" from a peptide vendor. Research-chemical vendors are not licensed pharmacies. The product has no compounding oversight, no sterility testing to USP <797> standards, and no verified API purity. Injecting such a product carries direct patient-safety risk, documented in FDA warning letters to multiple research-chemical suppliers [12].

What the Science Says About AOD-9604's Effectiveness

Legal status and clinical evidence are separate questions, but both matter for a complete picture.

Weight Loss Data

The METASIN-1 trial (N=300, 12 weeks, oral administration) showed a 2.8 kg greater weight loss vs. Placebo at the 1 mg daily dose [3]. An earlier phase II trial (N=109) found that 500 mcg subcutaneous daily dosing produced fat-mass reductions measured by DEXA at 12 weeks. Neither trial was powered for cardiovascular outcomes or long-term weight maintenance. No phase III data exist.

For comparison, semaglutide 2.4 mg (Wegovy) in STEP-1 (N=1,961, 68 weeks) produced 14.9% mean body-weight loss vs. 2.4% with placebo (P<0.001) [13]. AOD-9604's effect size, in the trials available, is considerably smaller.

Safety Profile in Clinical Data

Across the METASIN studies, adverse events were mild and comparable to placebo. No significant elevations in fasting glucose, insulin, or IGF-1 were recorded, which aligns with the proposed mechanism of action that separates the peptide from full-length hGH's metabolic side effects [3]. The available safety data cover only oral and short-term subcutaneous use in controlled settings, not the long-term injectable use now marketed by many telehealth clinics.

Cartilage and Joint Claims

Some peptide clinics also promote AOD-9604 for osteoarthritis, citing its proposed chondroprotective effects. A small animal study published in the context of intra-articular delivery showed reduced cartilage degradation markers in a rodent model. No peer-reviewed human RCT has replicated this in a clinical population [1]. Prescribing AOD-9604 for joint indications in Maryland patients falls outside any evidence-supported use.

How to Access AOD-9604 Legally in Maryland (The Realistic Path)

Given the 503A prohibition, the realistic legal path in Maryland is narrow but not entirely closed.

Step 1: Establish Care With a Licensed Maryland Prescriber

The prescriber must hold an active Maryland medical license (MD, DO, NP, or PA with prescriptive authority). A documented clinical evaluation, including BMI, metabolic labs, and a discussion of weight-management history, is required before any prescription [10].

Step 2: Confirm the Pharmacy's Compliance Status

Ask the prescriber which compounding pharmacy they use. Verify that the pharmacy holds a Maryland Board of Pharmacy license or is registered as a 503B outsourcing facility with the FDA. The FDA's database of registered 503B outsourcing facilities is publicly searchable at fda.gov [5]. If the pharmacy cannot demonstrate one of these credentials, do not proceed.

Step 3: Understand What You Are Actually Getting

Because AOD-9604 is on the 503A prohibited list, a compliant prescription may require substituting a different peptide or formulation. Discuss alternatives with your prescriber. Tesamorelin, for example, is FDA-approved and available through standard pharmacy channels [11]. CJC-1295 and ipamorelin blends occupy their own complex regulatory positions and should be evaluated the same way.

Step 4: Avoid Research-Chemical Sources

The FDA has issued warning letters to multiple vendors selling peptides labeled "not for human use." These products carry no quality guarantees. Bacteriostatic water used for reconstitution, vial sterility, and API concentration are unverified. One FDA laboratory analysis of research-chemical peptides found concentration variances of 30% to 200% from label claims [12].

Key Regulatory Dates Maryland Patients Should Know

• 2015. Metabolic Pharmaceuticals filed GRAS self-affirmation for oral AOD-9604 as a food ingredient. This is not a drug approval.
• 2021. FDA Pharmacy Compounding Advisory Committee (PCAC) reviewed AOD-9604 for the 503A bulks list. Initial recommendation was to gather more data.
• 2023. FDA finalized its decision: AOD-9604 is placed on the category 2 list of bulk substances that are NOT appropriate for 503A compounding because the clinical evidence base is insufficient to establish safety and effectiveness [6].
• Ongoing. Some 503A pharmacies continue compounding AOD-9604, asserting various legal arguments. FDA enforcement has not been uniform. The legal risk remains real.

A Note on Maryland's Broader Peptide Therapy Environment

Maryland sits within a regulatory environment that is stricter than some Southern and Mountain West states where state pharmacy boards have been slower to align with FDA bulks-list decisions. The Maryland Board of Pharmacy has historically moved in step with USP standards updates [9], which suggests it will enforce the 503A prohibition when specific pharmacies are reviewed.

The state has also been active in addressing compounding violations. In 2023, the Board took action against multiple in-state pharmacies for sterility violations under USP <797> [9]. That enforcement culture matters for patients evaluating which pharmacy to trust.

A Maryland patient seeking weight-management support has FDA-approved options with far stronger evidence, including semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and orlistat. These are available through standard prescription channels and telehealth platforms operating legally in the state.